GC Green Cross Launches 'Rozetel', a Triple Combination Drug for Hyperlipidemia and Hypertension

[Asia Economy Reporter Lee Gwan-joo] GC Green Cross announced on the 2nd that it has officially launched 'Rozetel,' a triple combination drug for hyperlipidemia and hypertension.

Rozetel is a triple combination drug containing rosuvastatin, ezetimibe, and telmisartan. This is the first time a triple combination drug with these components for hyperlipidemia and hypertension has been released domestically.

Rosuvastatin reduces low-density lipoprotein cholesterol (LDL-C) levels, which cause arteriosclerosis, ezetimibe inhibits the absorption of cholesterol in the small intestine to lower blood LDL-C, and telmisartan maintains blood pressure-lowering effects for more than 24 hours, enabling stable blood pressure control.

In clinical trials, the new product demonstrated superiority in improving lipid levels and lowering blood pressure compared to the control groups receiving rosuvastatin-ezetimibe or telmisartan alone, proving it to be an effective treatment option for patients with hyperlipidemia and hypertension.

A GC Green Cross official stated, “Rozetel’s excellent product quality and economical pricing compared to single-agent administration will provide patients with a useful treatment option.”

With the launch of this new product, GC Green Cross has established a metabolic syndrome lineup including hyperlipidemia treatments such as ‘Dabiduo,’ ‘Azetduo,’ and ‘Neoato,’ hypertension treatments like ‘Neokande,’ ‘Kandepin,’ and the hyperlipidemia-hypertension combination drug ‘Rotakan.’ Additionally, the company has applied for product approval for ‘Rozetelpine’ (rosuvastatin, ezetimibe, telmisartan, amlodipine), a quadruple combination drug for hyperlipidemia and hypertension.

This content was produced with the assistance of AI translation services.